In the Spotlight...
Targeted TNF Potentiates the Activity of Bispecific T-cell Engagers in Solid Tumors by Turning Cold Tumors Hot
The circadian gene Dec2 promotes pancreatic cancer progression and dormancy through immune evasion
Krüppel-like factor 2 programs early exhausted T cell states and restrains antiviral immunity
Time-of-day of first checkpoint inhibitor dose influences clinical outcomes and immune responses in hepatocellular carcinoma
Previous Digests
No cDC1, no worries: cDC2 and cross-dressing prime T cells in response to mRNA-LNP vaccination
April 29, 2026
cDC1s play essential roles in CD8+ T cell priming in response to protein- and DNA-based vaccination. However, whether mRNA vaccines function via a similar mechanism remains unknown. In a recent Nature publication, Jo et al. uncovered the mechanisms of...
Agonist anti-CD40 converts Tregs from foes to friends
April 22, 2026
Recent investigations into the use of agonist anti-CD40 for cancer immunotherapy have shown that this treatment not only enhances APC functions, but also reduces regulatory T cells (Tregs) within the tumor microenvironment (TME), despite a lack of CD40 on...
Stopping the shredder to unlock a novel source of valuable neoantigens
April 15, 2026
Inadequate neoantigen presentation in cancer hampers the endogenous antitumor immune response and the efficacy of immunotherapy. One mechanism that limits the production of immune-targetable antigens is nonsense-mediated mRNA decay (NMD). NMD degrades transcripts with premature termination codons (PTCs), eliminating...
Watch ACIR in action
In November 2019, ACIR received the Visionary Award from the Cambridge Chamber of Commerce.
Watch the 3-minute video explaining ACIR's mission and goal:
In September 2020, ACIR was featured in the documentary The American Dream on Bloomberg TV.
Watch the 6-minute segment on the story behind your favorite digest here:
About ACIR
ACIR's mission is to fast-track cancer immunotherapy research by helping researchers stay on top of the new literature in this fast-moving and multifaceted field, fostering their creativity and productivity in bringing us ever closer to curing this deadly disease.
Ute Burkhardt
Ed Fritsch
Lauren Hitchings
Gaëlle Llambi
Maartje Wouters
Alex Najibi
Katherine J. Turner
Stan Wolf
Paula Hochman
Shishir Pant
Nathan Suek
Morgan Janes
TESTIMONIALS
I'm a big fan of ACIR. I enjoy their weekly newsletters with clear, concise, and insightful summaries, complemented by excellent images. I've even used the images in some of my presentations to explain complex cancer immunotherapy findings. In our rapidly evolving field, their reliable and well-curated updates are invaluable.
Richard W. Vague Professor in Immunotherapy; Professor of PL&M; Director, Center for Cellular Immunotherapies; Director, Parker Institute for Cancer Immunotherapy; University of Pennsylvania Perelman School of Medicine. (Supporter since 2025).
Current Sponsors
